5-bromo-1-methoxy-2,3-dimethylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-bromo-1-methoxy-2,3-dimethylbenzene
• 化学式: C₉H₁₁BrO
• 分子量: 215.09
• InChiKey: MGXQTTXRXXGTJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-bromo-1-methoxy-2,3-dimethylbenzene 在 乙酸酐 作用下， 以 水 、 甲苯 、 叔丁醇 为溶剂， 反应 54.0h， 生成 6-bromo-2-(4-decylphenyl)-4-methoxyisoindoline-1,3-dione
  参考文献：
  名称：

  Nickel-catalyzed Decarbonylative Polymerization of 5-Alkynylphthalimides: A New Methodology for the Preparation of Polyheterocycles

  摘要：

  开发了一种镍催化的去羰基环加成反应，5-炔基邻苯二甲酰亚胺反应生成了一种新型聚异喹啉。首次证明了去羰基环加成可以作为制备杂环聚合物的聚缩合基本过程。

  DOI：

  10.1246/cl.2012.1566
• 作为产物：
  描述：

  4-溴-1,2-二甲苯 在 硫酸 、 platinum on activated charcoal 、 氢气 、 硝酸 、 potassium carbonate 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 70.0 ℃ 、101.33 kPa 条件下， 反应 37.0h， 生成 5-bromo-1-methoxy-2,3-dimethylbenzene
  参考文献：
  名称：

  Nickel-catalyzed Decarbonylative Polymerization of 5-Alkynylphthalimides: A New Methodology for the Preparation of Polyheterocycles

  摘要：

  开发了一种镍催化的去羰基环加成反应，5-炔基邻苯二甲酰亚胺反应生成了一种新型聚异喹啉。首次证明了去羰基环加成可以作为制备杂环聚合物的聚缩合基本过程。

  DOI：

  10.1246/cl.2012.1566

文献信息

• 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20020173517A1

  公开（公告）日：2002-11-21

  A compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: 1 wherein R 1 represents a hydrogen atom or a carboxyl-protecting group, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a hydroxyl group, R 3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group, a cyano group, a hydroxyl group or an amino group; R 4 represents a hydrogen atom, an amino-protecting group, an alkyl group or a cycloalkyl group, and R 5 represents a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an alkoxy group, an alkylthio group, a hydroxyl group, an imino group or an amino group.

  化合物的化学式（I）或其药用盐表示为：其中R1代表氢原子或羧基保护基团，R2代表氢原子、卤原子、低碳基团、低氧基团或羟基，R3代表氢原子、卤原子、低碳基团、低氧基团、低硫基团、硝基、氰基、羟基或氨基；R4代表氢原子、氨基保护基团、烷基或环烷基，R5代表氢原子、卤原子、烷基、烯基、环烷基、芳基、氧基、硫基、羟基、亚胺基或氨基。
• 4-oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure
  申请人：SATO Pharmaceutical Co., Ltd.

  公开号：US06525066B2

  公开（公告）日：2003-02-25

  A compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom or a carboxyl-protecting group, R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a hydroxyl group, R3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group, a cyano group, a hydroxyl group or an amino group; R4 represents a hydrogen atom, an amino-protecting group, an alkyl group or a cycloalkyl group, and R5 represents a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an alkoxy group, an alkylthio group, a hydroxyl group, an imino group or an amino group.

  以下式(I)所表示的化合物或其药学上可接受的盐： 其中，R1代表氢原子或羧基保护基，R2代表氢原子、卤素原子、较低的烷基基团、较低的烷氧基团或羟基基团，R3代表氢原子、卤素原子、较低的烷基基团、较低的烷氧基团、较低的烷基硫基团、硝基基团、氰基团、羟基基团或氨基基团；R4代表氢原子、氨基保护基、烷基或环烷基，R5代表氢原子、卤素原子、烷基、烯基、环烷基、芳基、烷氧基、烷硫基、羟基、亚胺基或氨基基团。
• 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE
  申请人：Sato Pharmaceutical Co. Ltd.

  公开号：EP1227096B1

  公开（公告）日：2004-09-22
• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20170260176A1

  公开（公告）日：2017-09-14

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
• US6525066B2
  申请人：——

  公开号：US6525066B2

  公开（公告）日：2003-02-25